Efficacy of azithromycin in the treatment of bronchiectasis

Anthony, Albert Iruthiaraj Lourdesamy; Muthukumaru, Umadevi

doi:10.1111/resp.12375

Cited by 20 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We identified eight systematic reviews [65][66][67][68][69][70][71][72] and 17 relevant studies for this clinical question [36,52,[73][74][75][76][77][78][79][80][81][82][83][84][85][86]. Our evidence summary suggests that long-term antibiotic use, pooling both inhaled and oral antibiotic data, reduces the number of exacerbations, time to first exacerbation, sputum purulence and breathlessness in adults with bronchiectasis; however, they are also associated with more adverse events and bacterial resistance.…”

Section: Recommendationsmentioning

confidence: 99%

European Respiratory Society guidelines for the management of adult bronchiectasis

et al. 2017

View full text Add to dashboard Cite

Bronchiectasis in adults is a chronic disorder associated with poor quality of life and frequent exacerbations in many patients. There have been no previous international guidelines.The European Respiratory Society guidelines for the management of adult bronchiectasis describe the appropriate investigation and treatment strategies determined by a systematic review of the literature.A multidisciplinary group representing respiratory medicine, microbiology, physiotherapy, thoracic surgery, primary care, methodology and patients considered the most relevant clinical questions (for both clinicians and patients) related to management of bronchiectasis. Nine key clinical questions were generated and a systematic review was conducted to identify published systematic reviews, randomised clinical trials and observational studies that answered these questions. We used the GRADE approach to define the quality of the evidence and the level of recommendations. The resulting guideline addresses the investigation of underlying causes of bronchiectasis, treatment of exacerbations, pathogen eradication, long term antibiotic treatment, anti-inflammatories, mucoactive drugs, bronchodilators, surgical treatment and respiratory physiotherapy.These recommendations can be used to benchmark quality of care for people with bronchiectasis across Europe and to improve outcomes.

show abstract

Section: Recommendationsmentioning

confidence: 99%

European Respiratory Society guidelines for the management of adult bronchiectasis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In contrast to studies investigating the benefits of a single AC session, in which an increase in expectorated sputum was desired, we considered a reduction in 24-hour sputum quantity to reflect less inflammation and a beneficial outcome in bronchiectasis. A reduction in sputum volume was seen in several studies of long-term treatments in bronchiectasis [34][35][36][37][38][39][40] , including mannitol, a mucoactive agent 34,35 . The recruited bronchiectasis patients were either newly diagnosed or referred.…”

Section: Discussionmentioning

confidence: 99%

4-week daily airway clearance using oscillating positive-end expiratory pressure versus autogenic drainage in bronchiectasis patients: a randomised controlled trial

et al. 2021

View full text Add to dashboard Cite

BackgroundAirway clearance (AC) is a fundamental component of bronchiectasis care. Lung clearance index (LCI) is a measurement of ventilation inhomogeneity. Its responsiveness to long-term AC is unknown. We aimed to compare two methods of daily AC over four weeks: autogenic drainage (AD) and oscillating positive airway pressure (oPEP), and to to determine effects of AC on LCI and clinical outcomes.MethodsAdults with bronchiectasis naive to airway clearance were randomised to daily AC with either AD or oPEP. Difference in LCI as primary outcome, spirometry, sputum volume and purulence, and quality of life were evaluated at randomisation and after four weeks of AC.ResultsFifty-one patients (32 women, 19 men, mean age 66.2±12.8 years) were randomised and 49 completed the study (25 AD, 24 oPEP). The LCI and forced expiratory volume in the first second (FEV1) did not change between visits between groups (difference between groups 0.02), nor between visits in either group. Sputum quantity decreased in 12/24 (50%) of the oPEP group, and in 6/25 (24%) of the AD group (p=0.044). The “treatment burden” worsened or was unchanged in 70% of participants randomised to AD and 55% randomised to oPEP (p=0.038).ConclusionSputum quantity decreased in more participants randomised to oPEP group after one month of daily AC, with a better treatment burden. The effects of four weeks of AC on LCI were not significant in either treatment group.

show abstract

“…По результатам большинства опубликованных исследований [63,67,68] и данных метаанализа базы данных Cоchrane [62], при терапии макролидами длительностью от 8 нед. до 6 мес.…”

Section: макролидыunclassified

Current approaches to pharmacological treatment of adult patients with bronchiectasis

Чикина

Авдеев

2019

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

Бронхоэктазы (БЭ)-это хроническое бронхолегочное заболевание, которое характеризуется кашлем, продукцией мокроты и рецидивирующей бронхиальной инфекцией, а также патологической дилатацией бронхов при рентгеновском исследовании. БЭ могут сопровождать множество разнообразных заболеваний и патологических состояний. Дилатация бронхов может возникать при первичном структурном дефекте бронхиальной стенки, патологическом повышении давления внутри бронха или

show abstract

Efficacy of azithromycin in the treatment of bronchiectasis

Cited by 20 publications

References 6 publications

European Respiratory Society guidelines for the management of adult bronchiectasis

European Respiratory Society guidelines for the management of adult bronchiectasis

4-week daily airway clearance using oscillating positive-end expiratory pressure versus autogenic drainage in bronchiectasis patients: a randomised controlled trial

Current approaches to pharmacological treatment of adult patients with bronchiectasis

Contact Info

Product

Resources

About